Masson / Shutterstock.com
The UK’s vote to leave the EU has triggered an immediate need for innovative life sciences companies to evaluate the impact on their patent strategies, argues Laetitia Benard of Allen & Overy.
On June 24 the UK confirmed its vote to leave the EU, the first step in a process that is likely to lead to the biggest de-merger in history: the world’s fifth largest economy (the UK) leaving the world’s largest economic grouping (the EU).
EU law continues to apply until the UK formally exits the union. The key unknown is which post-‘Brexit’ model will be negotiated. At this point, it is difficult to predict how, or when, the exit will happen. What is clear, however, is that Brexit, in whatever form it ultimately takes, will have an impact on the legal rights and obligations of parties in the life sciences sector. It is also clear that the uncertainty caused by the ‘Leave’ vote is problematic for many parties, both in the immediate aftermath of the vote and as the details of the UK’s exit are ironed out.
Brexit implications for EU patent strategy
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Laetitia Benard, Allen & Overy, SPCs, EEA, UPC system, patent, YouGov, TRIPS Agreement, EU law, patent, trademark, copyright, life sciences,